A new AI-powered method has demonstrated a breakthrough in detecting tumor DNA from blood tests, showing high sensitivity and accuracy. This technology, known as MRD-EDGE, could revolutionize the early detection and monitoring of cancer, including lung, breast, colorectal cancers, and precancerous conditions. It offers a promising advancement over traditional methods by identifying cancer recurrence months or even years earlier.
Researchers have developed an AI method that significantly improves the detection of tumor DNA in blood, enhancing early cancer detection and monitoring. This method, known as MRD-EDGE, has shown high effectiveness in lung, breast, and colorectal cancers by identifying recurrences earlier than conventional methods. A new artificial intelligence -powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence.
The new technology promises to improve cancer care with the very early detection of recurrence and close monitoring of tumor response during therapy. This breakthrough study was led by scientists at Weill Cornell Medicine, NewYork-Presbyterian, the New York Genome Center (NYGC), and Memorial Sloan Kettering Cancer Center (MSK). Enhancing Early Cancer Detection With AI In the study, which appears June 14 in Nature Medicine , the researchers showed that they could train a machine learning model, a type of artificial intelligence platform, to detect circulating tumor DNA (ctDNA) based on DNA sequen.
